uniQure (NASDAQ:QURE) Upgraded at Wells Fargo & Company

Wells Fargo & Company upgraded shares of uniQure (NASDAQ:QURE) from an equal weight rating to an overweight rating in a research report released on Monday, Marketbeat reports. They currently have $60.00 target price on the biotechnology company’s stock, up from their prior target price of $15.00.

QURE has been the topic of a number of other reports. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Mizuho restated a “neutral” rating and set a $12.00 target price (down from $33.00) on shares of uniQure in a report on Tuesday, March 3rd. Finally, Chardan Capital dropped their target price on uniQure from $53.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $43.25.

uniQure Trading Down 3.8%

Shares of QURE stock opened at $17.56 on Monday. uniQure has a 1-year low of $7.76 and a 1-year high of $71.50. The firm has a market cap of $1.10 billion, a PE ratio of -5.09 and a beta of 0.73. The company has a 50-day moving average of $21.67 and a two-hundred day moving average of $29.58. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. On average, analysts predict that uniQure will post -3.75 EPS for the current year.

Insider Buying and Selling

In other news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 12,000 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $108,720.00. Following the completion of the transaction, the chief financial officer directly owned 226,581 shares in the company, valued at $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 81,399 shares of company stock valued at $1,527,645 over the last ninety days. 4.79% of the stock is currently owned by corporate insiders.

Institutional Trading of uniQure

Hedge funds have recently added to or reduced their stakes in the stock. Flax Pond Capital LLC purchased a new stake in shares of uniQure in the fourth quarter valued at about $3,506,000. Seven Fleet Capital Management LP purchased a new position in uniQure during the fourth quarter worth about $209,000. Virtus Investment Advisers LLC lifted its position in uniQure by 91.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 13,636 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 6,520 shares during the period. SummitTX Capital L.P. boosted its holdings in uniQure by 386.3% in the 4th quarter. SummitTX Capital L.P. now owns 27,708 shares of the biotechnology company’s stock valued at $663,000 after purchasing an additional 22,010 shares in the last quarter. Finally, Suvretta Capital Management LLC purchased a new stake in uniQure in the 4th quarter valued at approximately $29,116,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Several analyst upgrades and bullish reports have pushed optimism around the company’s pipeline — Mizuho upgraded QURE to “outperform” with a $35 target (up from $12), and other firms (RBC, Wells Fargo, Chardan) have issued more favorable notes recently, supporting a rebound narrative for the stock. Mizuho Upgrade
• Positive Sentiment: H.C. Wainwright reaffirmed a Buy rating and kept a $70 price target, citing regulatory shifts and AMT‑130 outlook as catalysts that could drive long-term upside. H.C. Wainwright Note
• Neutral Sentiment: Shares previously spiked (~26% reported) on an FDA leadership shakeup that some investors hoped would favor uniQure’s Huntington’s therapy pathway — a short-term momentum event that may have already priced in expectations. MSN Coverage
• Negative Sentiment: Regulatory risk intensified after reports that the FDA publicly rebuked uniQure, alleging the company pushed “distorted” or “manipulated” data around the failed AMT‑130 program — a serious development that raises oversight, approval, and credibility concerns. FDA Allegation Report
• Negative Sentiment: Multiple plaintiff firms have filed or are soliciting investors for securities‑fraud class actions tied to uniQure’s FDA delays and share decline, creating legal overhang, potential liabilities, and continued headline risk that can pressure the stock. Kessler Topaz Filing
• Negative Sentiment: Short interest jumped significantly in February (over 17% increase), now representing ~21% of float — a condition that can amplify downside on negative news and reflects elevated bearish positioning.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.